ONCS signs cGMP manufacturing agreement with VGXI
The agreement uses VGXI’s patented DNA plasmid manufacturing process and leverages VGXI’s expertise for large-scale process development and clinical manufacturing for DNA IL-12 for use in OncoSec’s OMS
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.